RESUMO
Abstract Solubility of pharmaceutical drugs in organic solvents is one of the important parameters to understand the equilibrium concentration of solute-solvent, which helps optimize and design crystallization conditions to obtain the desired product crystals. In the present study, Chlorzoxazone (CHZ) is used as a model pharmaceutical compound to investigate the equilibrium solubility, the influence of solvent and the operating conditions on the shape, and the size distribution. The solubility of CHZ is determined in organic solvents like Isopropanol, Ethanol, and 2-Ethoxyethylacetate, Ethylacetate and Ethyllactate using shake flask method from -5ºC to 60ºC. The solubility of CHZ in these solvents shows an increasing trend as the temperature increases in the following order: ethyllactate + water (0.5+0.5) < ethylacetate < isopropanol < ethanol < 2-ethoxyethylacetate < ethyllactate + water (0.75+0.25). The solvents, isopropanol, ethanol, and ethyl lactate, produce needle-shaped crystals, while 2-ethoxyethylacetate and ethyl acetate tend to produce plate shaped crystals. CHZ crystals obtained from 2-ethoxyethylacetate tend to have plate shaped crystals with a lower aspect ratio and are selected for batch cooling crystallization experiments performed at different cooling rates, and agitation. It is found that the agitation at 300 rpm and the cooling rate 0.2ºC/min produce more uniform crystal size distribution
Assuntos
Solventes/classificação , Clorzoxazona/análise , Cristalização/classificação , Solubilidade , Preparações Farmacêuticas/administração & dosagemRESUMO
Lycopene was reported to influence some cytochrome P450 enzymes activity. The present study investigates the effect of lycopene on the pharmacokinetics of paracetamol and chlorzoxazone. Lycopene (20 mg/kg) was intra-peritoneally administered to two groups of rats for eight consecutive days and two other groups were given vehicle. On the eighth day, chlorzoxazone and paracetamol were separately intravenously administered to a lycopene group and a control group. Blood samples were collected at different time intervals, treated and analyzed using HPLC. The HPLC method used for paracetamol analysis was based on isocratic elution using a mobile phase consisting of water: methanol, (77:23 v/v) at a flow rate 1 mL min−1, Kromasil C18 column, and UV detection at 254 nm using caffeine as internal standard. About chlorzoxazone, separation was carried out using water: acetonitrile (60: 40, v/v) as the mobile phase at a flow rate 1 mL min−1, Inertsil ODS-3 C18 column, UV detection at 283 nm and esomeprazole as internal standard. Statistical analysis of the pharmacokinetic data using student t test showed a significant increase in AUC 0-t , AUC 0-Inf and t1/2 of paracetamol (P<0.05) and of chlorzoxazone (P<0.05) in the groups pretreated with lycopene (20 mg/kg), significant increase in the volume of distribution of paracetamol (P < 0.05), but no significant difference in that of chlorzoxazone. In other words, paracetamol and chlorzoxazone showed significant decrease (P < 0.05), respectively. These results demonstrate that treatment of rats with Lycopene (20mg/kg, ip) has a significant effect on the metabolic clearance and the pharmacokinetics of both drugs
Assuntos
Animais , Masculino , Ratos , Clorzoxazona/farmacocinética , Licopeno/química , Acetaminofen/farmacocinética , Taxa de Depuração Metabólica/efeitos dos fármacos , Cromatografia Líquida de Alta Pressão/métodos , Área Sob a CurvaRESUMO
CYP2E1 enzyme is related to nonalcoholic steatohepatitis (NASH) due to its ability for reactive oxygen species production, which can be influenced by polymorphisms in the gene. The aim of this study was to investigate hepatic levels, activity, and polymorphisms of the CYP2E1 gene to correlate it with clinical and histological features in 48 female obese NASH patients. Subjects were divided into three groups: (i) normal; (ii) steatosis; and (iii) steatohepatitis. CYP2E1 protein level was assayed in microsomes from liver biopsies, and in vivo chlorzoxazone hydroxylation was determined by HPLC. Genomic DNA was isolated for genotype analysis through PCR. The results showed that liver CYP2E1 content was significantly higher in the steatohepatitis (45%; p=0.024) and steatosis (22%; p=0.032) group compared with normal group. Chlorzoxazone hydroxylase activity showed significant enhancement in the steatohepatitis group (15%, p=0.027) compared with the normal group. c2 rare allele of RsallPstl polymorphisms but no C allele of Dral polymorphism was positively associated with CHZ hydroxylation, which in turn is correlated with liver CYP2E1 content (r=0.59; p=0.026). In conclusion, c2 allele is positively associated with liver injury in NASH. This allele may determine a higher transcriptional activity of the gene, with consequent enhancement in pro-oxidant activity of CYP2E1 thus affording liver toxicity.
Assuntos
Citocromo P-450 CYP2E1/metabolismo , Fígado Gorduroso/enzimologia , Hepatite/enzimologia , Fígado/enzimologia , Obesidade/enzimologia , Adulto , Estudos de Casos e Controles , Clorzoxazona/metabolismo , Cromatografia Líquida de Alta Pressão , Citocromo P-450 CYP2E1/genética , Fígado Gorduroso/patologia , Feminino , Frequência do Gene , Genótipo , Hepatite/patologia , Humanos , Hidroxilação/genética , Fígado/patologia , Obesidade/patologia , Polimorfismo GenéticoRESUMO
Highly purified rat-liver nuclei were previously shown to have nuclear ethanol (EtOH) metabolizing system able to bioactivate alcohol to acetaldehyde and 1-hydroxyethyl radicals. These reactive metabolites were able to covalently bind to nuclear proteins and lipids potentially being able to provoke oxidative stress of nuclear components. In this study, the above-mentioned possibility was explored. Sprague Dawley male rats (125-150 g) were fed a standard Lieber and De Carli liquid diet for 28 days. Controls were pair-fed with a diet, in which EtOH was isocalorically replaced with carbohydrate. The presence of a chlorzoxazone hydroxylase activity inducible by the repetitive EtOH drinking further suggested the presence of CYP2E1 in the highly purified nuclei. Nuclei from EtOH-drinking rats evidenced significantly increased susceptibility to a t-butyl hydroperoxide challenge as detected by chemiluminescence emission, increased formation of protein carbonyls, and decreased content of protein sulfhydryls. In contrast, no significant changes in the nuclear lipid hydroperoxides formation or even decreases in the 8-oxo-7,8-dihydro-2-deoxyguanosine were observed. No significant differences were observed in different parameters of the alkaline Comet assay. In immunohistochemical studies performed, no expression of p53 was observed in the livers of the animals under the experimental conditions tested. Since nuclear proteins and lipids are known to play a role in cell growth, differentiation, repair and signaling, their alterations by either oxidative stress, or by covalent binding might be of relevance to liver tumor promotion.
Assuntos
Núcleo Celular/metabolismo , Etanol/administração & dosagem , Fígado/metabolismo , Estresse Oxidativo/efeitos dos fármacos , 8-Hidroxi-2'-Desoxiguanosina , Animais , Clorzoxazona/análogos & derivados , Clorzoxazona/metabolismo , Ensaio Cometa , Citocromo P-450 CYP2E1/metabolismo , Interpretação Estatística de Dados , Desoxiguanosina/análogos & derivados , Desoxiguanosina/análise , Hepatócitos/citologia , Hepatócitos/metabolismo , Imuno-Histoquímica , Peroxidação de Lipídeos/efeitos dos fármacos , Fígado/química , Fígado/citologia , Masculino , Microssomos Hepáticos/química , Microssomos Hepáticos/metabolismo , Oxigenases de Função Mista/metabolismo , Carbonilação Proteica/efeitos dos fármacos , Ratos , Ratos Sprague-Dawley , Compostos de Sulfidrila/metabolismo , Proteína Supressora de Tumor p53 , terc-Butil Hidroperóxido/metabolismoRESUMO
CYP2E1 enzyme is related to nonalcoholic steatohepatitis (NASH) due to its ability for reactive oxygen species production, which can be influenced by polymorphisms in the gene. The aim of this study was to investigate hepatic levels, activity, and polymorphisms of the CYP2E1 gene to correlate it with clinical and histological features in 48 female obese NASH patients. Subjects were divided into three groups: (i) normal; (ii) steatosis; and (iii) steatohepatitis. CYP2E1 protein level was assayed in microsomes from liver biopsies, and in vivo chlorzoxazone hydroxylation was determined by HPLC. Genomic DNA was isolated for genotype analysis through PCR. The results showed that liver CYP2E1 content was significantly higher in the steatohepatitis (45 percent; p=0.024) and steatosis (22 percent; p=0.032) group compared with normal group. Chlorzoxazone hydroxylase activity showed significant enhancement in the steatohepatitis group (15 percent, p=0.027) compared with the normal group. c2 rare allele of RsallPstl polymorphisms but no C allele of Dral polymorphism was positively associated with CHZ hydroxylation, which in turn is correlated with liver CYP2E1 content (r=0.59; p=0.026). In conclusion, c2 allele is positively associated with liver injury in NASH. This allele may determine a higher transcriptional activity of the gene, with consequent enhancement in pro-oxidant activity of CYP2E1 thus affording liver toxicity.
Assuntos
Adulto , Feminino , Humanos , /metabolismo , Fígado Gorduroso/enzimologia , Hepatite/enzimologia , Fígado/enzimologia , Obesidade/enzimologia , Estudos de Casos e Controles , Cromatografia Líquida de Alta Pressão , Clorzoxazona/metabolismo , /genética , Fígado Gorduroso/patologia , Frequência do Gene , Genótipo , Hepatite/patologia , Hidroxilação/genética , Fígado/patologia , Obesidade/patologia , Polimorfismo GenéticoRESUMO
The inducibility of CYP2E1 was investigated in liver and peripheral lymphocytes of rats treated with benzene (0-10 mmol/kg body weight (bw), daily for 3 days, i.p., or 0 and 5 mmol/kg bw, daily for 14 days, i.p.) or toluene (0 and 5 mmol/kg bw, daily for 3 days, i.p.) and compared with that of pyridine (5 mmol/kg bw, i.p.) or acetone (5% in drinking water) both daily for 3 days. Acute benzene treatment (5 mmol/kg bw) increased both CYP2E1 apo-protein (2-fold) and p-nitrophenol hydroxylase (p-NPH) activity (1.4-fold) in liver, and CYP2E1 mRNA in both liver (2.2-fold) and peripheral lymphocytes (2.9-fold). The response to toluene was qualitatively similar, although smaller than that to benzene. As expected, acetone and pyridine treatments resulted in a 2- to 3-fold increase of p-NPH activity and CYP2E1 apo-protein content in liver, but not the mRNA levels. In addition, acute benzene and acetone treatments increased the 6-hydroxychlorzoxazone/chlorzoxazone metabolic ratio 1.6- and 3.1-fold, respectively. The subchronic treatment with benzene increased CYP2E1 mRNA and apo-protein from days 2 and 3 to day 14, respectively, whereas the enzyme activity increased transiently on days 3 and 5 only. These results show that acute/subacute benzene and acute toluene treatments induce CYP2E1 expression probably through a similar mechanism which might be different from that of pyridine or acetone, in that the former increase mRNA levels, both in liver and in peripheral lymphocytes, whereas the latter stabilized the apo-protein.
Assuntos
Benzeno/farmacologia , Clorzoxazona/análogos & derivados , Citocromo P-450 CYP2E1/metabolismo , Fígado/enzimologia , Linfócitos/enzimologia , Acetona/farmacologia , Animais , Western Blotting , Separação Celular , Clorzoxazona/metabolismo , Citocromo P-450 CYP2E1/biossíntese , Citocromo P-450 CYP2E1/genética , Indução Enzimática/efeitos dos fármacos , Regulação Enzimológica da Expressão Gênica , Técnicas In Vitro , Indicadores e Reagentes , Fígado/efeitos dos fármacos , Linfócitos/efeitos dos fármacos , Masculino , Microssomos Hepáticos/efeitos dos fármacos , Microssomos Hepáticos/enzimologia , Piridinas/farmacologia , RNA Mensageiro/biossíntese , Ratos , Ratos Wistar , Reação em Cadeia da Polimerase Via Transcriptase Reversa , Tolueno/farmacologia , Aumento de Peso/efeitos dos fármacosRESUMO
OBJECTIVES: Population differences in the activity of various cytochrome P450 (CYP) enzymes have been demonstrated on the basis of either genetic or environmental determinants. Hispanics are a large demographic group both worldwide and within the United States; hence the possibility of differences in metabolism between one such group-Mexicans-and a European-derived population was determined with respect to CYP2E1 and CYP3A. METHODS: Young healthy Mexican immigrants living in Los Angeles, Calif, who had maintained a traditional diet were compared with previously and identically studied groups of age-, sex-, and weight-matched European Americans who resided in middle Tennessee and ate a "western" diet (15 men and 15 women). In one study carried out in 15 women, the disposition of chlorzoxazone after an oral dose (250 mg) was compared. In the other investigation, all of the 15 subjects were men and received intravenous [(15)N(3)]-labeled midazolam (1 mg) and oral midazolam (2 mg) simultaneously to characterize the disposition of benzodiazepine in the two populations. RESULTS: Plasma concentration-time profiles of chlorzoxazone and its 6-hydroxy metabolite and the 0- to 24-hour urinary recovery of the latter were not different between Mexicans and European Americans. This indicates that CYP2E1 activity is similar in the two populations. Similarly, no significant intergroup differences were noted in the plasma concentration-time profiles of midazolam after either intravenous or oral administration. Accordingly, CYP3A does not appear to be different between Mexicans and European Americans. CONCLUSIONS: Similarity in the metabolism of chlorzoxazone between Mexicans and European Americans suggests that the risk associated with CYP2E1-mediated activation of procarcinogens is not different between these two populations. Likewise, the absence of any difference in the disposition of midazolam indicates that, from a pharmacokinetic standpoint, dosages of drugs metabolized by CYP3A need not be different between Mexicans and European Americans.
Assuntos
Hidrocarboneto de Aril Hidroxilases , Citocromo P-450 CYP2E1/metabolismo , Sistema Enzimático do Citocromo P-450/metabolismo , Americanos Mexicanos , Oxirredutases N-Desmetilantes/metabolismo , População Branca , Adulto , Clorzoxazona/farmacocinética , Citocromo P-450 CYP3A , Europa (Continente) , Feminino , Interações Alimento-Droga/fisiologia , Humanos , Los Angeles , Masculino , Americanos Mexicanos/genética , Midazolam/farmacocinética , Pessoa de Meia-Idade , Estatísticas não Paramétricas , População Branca/genéticaRESUMO
Con el objetivo de valorar la seguridad, tolerancia y eficacia de ketoprofeno más clorzoxazona vs diclofenaco en pacientes con síndrome doloroso de la columna vertebral, se realizó un estudio clínico doble ciego, prospectivo, longitudinal, controlados e inferencial. Para ellos, se incluyeron 50 pacientes que se distribuyeron en dos grupos: el A recibió dosis diaria de 50 mg de ketoprofeno más 250 clorzoxazona dos veces al día desde el inicio hasta el final del estudio, y el B 200 mg de diclofenaco al día. Se realizó examen clínico el día cero y 15 del tratamiento y luego periódicamente hasta un total de 12 semanas. Posterior a dicho periodo, en la primera evaluación se observó diferencia entre los grupos de tratamiento. En el grupo tratado con ketoprofeno más clorzoxazona disminuyó el dolor a la palpación, movimiento e inflamación y mejoró la función articular, no así con diclofenaco. Se observaron diferencias entre los dos grupos, tanto en el tratamiento como en respuesta sintomatológica que fueron significativas durante el estudio. Después de ocho semanas de tratamiento 70 por ciento del grupo con ketoprofeno más con diclofenaco. Estas sifras aumentaron hasta 95 por ciento de recuperacion casi completa en el grupo de ketoprofeno más clorzoxazona, mientras que 70 por ciento del grupo con diclofenaco no mejoró en absouluto como lodemuestran las estadísticas de respuesta. En ambos casos, la diferencia fue estadísticamente significativa. La tolerancia de ketoprofeno más clorzoxazona se consideró excelente. En ambos grupos se observaron incidencias similares de irritación gástrica en 4 por ciento de los casos. Estos resultados confirman la excelente seguridad, toleranacia y eficacia de ketoprofeno más clorzoxazona en el tratamiento del síndrome doloroso de la columna vertebral